Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib.

MLA

Frankel, Arthur E., et al. “Response to Pegylated Interferon in a COVID‐19–positive Elderly Woman with Primary Myelofibrosis Treated with Ruxolitinib.” Clinical Case Reports, vol. 9, no. 4, Apr. 2021, pp. 2228–35. EBSCOhost, https://doi.org/10.1002/ccr3.3997.

APA

Frankel, A. E., Reddy, R., DeSuza, K. R., Deeb, K., Carlin, A. F., Smith, D., Xie, Y., Naik, E., Silver, R. T., & Hasselbalch, H. C. (2021). Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib. Clinical Case Reports, 9(4), 2228–2235. https://doi.org/10.1002/ccr3.3997

Chicago

Frankel, Arthur E., Renuka Reddy, Kayla R. DeSuza, Khaled Deeb, Aaron F. Carlin, Davey Smith, Yushuang Xie, Eknath Naik, Richard T. Silver, and Hans C. Hasselbalch. 2021. “Response to Pegylated Interferon in a COVID‐19–positive Elderly Woman with Primary Myelofibrosis Treated with Ruxolitinib.” Clinical Case Reports 9 (4): 2228–35. doi:10.1002/ccr3.3997.